Core Viewpoint - The People's Bank of China (PBOC) emphasizes the need for continued financial reform and opening up in 2026, focusing on enhancing supervision and management across various financial markets and supporting the development of international financial centers [1] Group 1: Financial Reform and Supervision - The PBOC plans to strengthen supervision and management of interbank bond markets, money markets, foreign exchange markets, bill markets, gold markets, and related derivatives [1] - There will be a focus on enhancing the overall regulatory framework for financial infrastructure [1] Group 2: International Financial Centers - The PBOC aims to deepen high-level opening of financial markets and optimize mechanisms like "Bond Connect" and "Swap Connect" [1] - Support will be provided for the construction of the Shanghai International Financial Center while maintaining the stability and prosperity of the Hong Kong financial market [1] Group 3: Cross-Border Financial Services - The PBOC will facilitate the use of the Renminbi in trade and investment by enhancing the role of central bank currency swaps and improving cross-border financial services [1] - There will be efforts to improve the infrastructure for cross-border use of the Renminbi and welcome more eligible foreign entities to issue Panda bonds [1] - Expansion of the rapid payment system's interconnectivity and promotion of QR code interoperability cooperation are also planned [1]

北京商报讯（记者 宋亦桐）1月6日，国家金融监督管理总局陕西监管局公布的行政处罚信息公示表显 示，交通银行股份有限公司陕西省分行因"发放固定资产贷款不审慎、银行承兑汇票授信后管理不到 位、超过借款人实际需求发放流动资金贷款、项目贷款贷后管理不到位"违法违规行为，被罚款253万 元；监管机构对相关责任人员牛博、姚淑芳分别给予警告，对林雅欣给予警告并罚款5万元。 ...

北京商报讯（记者 孟凡霞 周义力）1月6日，国家金融监督管理总局海南监管局发布《关于海南农商银 行吸收合并保亭融兴村镇银行的批复》，同意海南农商银行吸收海南保亭融兴村镇银行，并承接海南保 亭融兴村镇银行清产核资后的资产、负债、业务以及其他各项权利义务。 ...

Core Viewpoint - The first IPO application for the ChiNext board in 2026 is set to be reviewed, with Hangzhou Gaote Electronics Co., Ltd. scheduled for examination on January 13, 2026 [1] Company Overview - Hangzhou Gaote Electronics is recognized as a national high-tech enterprise and a specialized and innovative "little giant" company, focusing on providing new energy industry products related to safe, reliable, efficient, stable, and economically viable battery management systems [1] IPO Details - The company’s IPO was accepted on June 23, 2025, and entered the inquiry stage on July 9, 2025 [1] - Gaote Electronics aims to raise 850 million yuan, which will be allocated to the construction of an intelligent manufacturing center for battery management systems and to supplement working capital after deducting issuance costs [1]

Core Viewpoint - Guanshang Technology (301213) plans to acquire 100% of Jinzhou Liaojing Electronic Technology Co., Ltd. through a combination of share issuance and cash payment, with the stock resuming trading on January 7 [1] Group 1: Acquisition Details - The transaction is expected to constitute a major asset restructuring and related party transaction, but it will not qualify as a restructuring listing [1] - The acquisition aims to enhance Guanshang Technology's ability to provide a one-stop solution of "core components + intelligent system platform + full life cycle management" to military and defense clients [1] Group 2: Strategic Implications - By acquiring Liaojing Electronic, which specializes in military semiconductor research and production, Guanshang Technology aims to strengthen customer loyalty and build significant competitive barriers [1] - The company anticipates that this move will expand its overall sales scale and further enhance its sustainable profitability and core competitiveness [1]

北京商报讯(记者丁宁)1月6日晚间，伟思医疗(688580)发布公告称，公司股票连续三个交易日内收盘价 格涨幅偏离值累计超过30%，属于股票交易异常波动。 因涉及脑机接口概念，伟思医疗已连续两个交易日涨停收盘，截至1月6日收盘，伟思医疗报69.7元/ 股，涨幅为20.01%。 伟思医疗表示，公司主营业务聚焦于康复医疗器械的研发、生产与销售，产品广泛应用于精神康复、盆 底及产后康复、神经康复等领域。截至2025年末，公司在脑机接口领域的新产品仍处于市场培育初期， 主要布局非侵入式技术路线，与当前国际领先的侵入式脑机接口存在显著技术路径差异，相关产品尚未 实现规模化销售，对整体营业收入的贡献仍较为有限。 ...

Core Viewpoint - Xuantai Pharmaceutical (688247) has received approval from the National Medical Products Administration for the marketing of injectable isavuconazole, which is expected to enhance the company's product line and competitiveness, positively impacting future operating performance [1] Group 1 - The company announced the approval of injectable isavuconazole on January 6 [1] - The approval is seen as a strategic move to enrich the company's product offerings [1] - The introduction of this product is anticipated to have a positive effect on the company's future financial performance [1]

Core Viewpoint - Tianbang Food (002124) reported its sales performance for December 2025 and the entire year, indicating a decline in sales prices and a mixed performance in sales volume compared to previous periods [1] Group 1: December 2025 Sales Performance - The company sold 662,300 pigs in December 2025, including 238,000 piglets, generating a revenue of 613 million yuan [1] - The average selling price was 11.87 yuan/kg, with the average price for fat pigs at 11.23 yuan/kg, showing a month-on-month decline of 2.29% in sales volume, 6.27% in revenue, and 1.97% in average price [1] Group 2: Annual Sales Performance for 2025 - For the full year 2025, the company sold 6,663,500 pigs, including 2,393,600 piglets, with total revenue reaching 7.959 billion yuan [1] - The average selling price for the year was 14.65 yuan/kg, while the average price for fat pigs was 13.54 yuan/kg, reflecting a year-on-year increase of 11.21% in sales volume but declines of 8.95% in revenue and 17.85% in average price [1] Group 3: Slaughtering Data - In December 2025, the company slaughtered 149,500 pigs, with a total of 1,601,200 pigs slaughtered throughout the year [1]

Core Viewpoint - The company, Haikang (002653), announced that its subsidiary Sichuan Haikang Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration regarding the acceptance of the registration application for the drug HSK39297, aimed at treating adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitors [1] Group 1 - The drug HSK39297 is classified as a Class 1 chemical drug according to China's new chemical drug registration classification regulations [1] - HSK39297 is the first-tier CFB inhibitor targeting PNH in China, addressing a significant unmet clinical need [1] - The market outlook for HSK39297 is positive due to the high demand for treatment options in this therapeutic area [1]

Core Viewpoint - Pro Pharmaceutical (000739) has signed a strategic cooperation framework agreement with Xi'an New Tong Pharmaceutical Research Co., Ltd. to engage in long-term collaboration on innovative drug research and development and custom manufacturing projects (CDMO) [1] Group 1: Strategic Cooperation - The agreement establishes a strategic partnership between Pro Pharmaceutical and Xi'an New Tong, focusing on long-term collaboration in CDMO projects [1] - This collaboration is expected to enhance Pro Pharmaceutical's CDMO business competitiveness and facilitate its expansion in this sector [1] Group 2: Xi'an New Tong's IPO - Xi'an New Tong is currently preparing for an IPO on the Sci-Tech Innovation Board, with its application accepted on December 29, 2025, aiming to raise 900 million yuan [1]